文献速递妇科肿瘤

未知子宫恶性肿瘤患者行子宫切除或肌瘤剔除时旋切术与死亡率的相关性

Association Between Power Morcellation and Mortality in Women With Unexpected Uterine Cancer Undergoing Hysterectomy or Myomectomy.
PubMed 文献 · J Clin Oncol · 2019-09-16

该研究通过纽约州住院记录与肿瘤登记数据联动,纳入843例隐匿性子宫内膜癌和334例隐匿性子宫肉瘤患者,比较腹腔镜次全子宫切除/腹腔镜肌瘤剔除(作为无保护旋切的替代指标)与不涉及旋切的腹式手术的死亡风险。结果显示,在隐匿性子宫肉瘤患者中,无保护旋切与疾病特异性死亡率升高相关,尤其在平滑肌肉瘤亚组;在隐匿性子宫内膜癌患者中未发现显著关联。

要点

  • 隐匿性子宫肉瘤患者中,腹腔镜次全子宫切除/肌瘤剔除与疾病特异性死亡率升高相关(aHR 2.66)。
  • 平滑肌肉瘤亚组中,该术式与次全腹式子宫切除相比aHR 3.64,与全腹式子宫切除相比aHR 4.66。
  • 隐匿性子宫内膜癌患者中手术方式与疾病特异性死亡率无显著关联。

核心结论

  • 无保护旋切与隐匿性子宫肉瘤患者死亡风险升高相关,尤其平滑肌肉瘤亚组。
  • 隐匿性子宫内膜癌患者中未观察到手术方式与疾病特异性死亡的显著关联。

研究设计与样本

  • 回顾性队列研究,联动纽约州住院出院记录与肿瘤登记数据。
  • 采用多因素Cox回归和倾向评分方法调整患者特征。

主要发现

  • 隐匿性子宫肉瘤中,腹腔镜次全子宫切除/肌瘤剔除(LSH/LM)相比全腹式子宫切除(TAH)疾病特异性死亡aHR 2.66(95%CI 1.11-6.37),5年疾病特异性生存调整差异-19.4%(95%CI -35.8%至-3.1%)。
  • 平滑肌肉瘤亚组中,LSH/LM相比次全腹式子宫切除疾病特异性死亡aHR 3.64(95%CI 1.50-8.86),5年生存调整差异-31.2%(95%CI -50.0%至-12.3%)。
  • 平滑肌肉瘤亚组中,LSH/LM相比TAH疾病特异性死亡aHR 4.66(95%CI 1.97-11.00),5年生存调整差异-37.3%(95%CI -54.2%至-20.3%)。
  • 隐匿性子宫内膜癌中,手术方式与疾病特异性死亡率无显著关联。

临床怎么用

  • 对拟行子宫切除或肌瘤剔除的患者,应术前评估隐匿性子宫肉瘤风险并告知无保护旋切的潜在预后风险。
  • 疑诊或高危子宫肉瘤患者应避免使用无保护旋切,优先选择不涉及旋切的手术方式。

局限性

  • 研究为回顾性观察性设计,LSH/LM作为无保护旋切的替代指标可能存在错分。
  • 结论主要基于纽约州数据库,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite concerns that power morcellation may adversely affect prognosis of patients with occult uterine cancer, empirical evidence has been limited and inconclusive. In this study, we aimed to determine whether uncontained power morcellation at the time of hysterectomy or myomectomy is associated with increased mortality risk in women with occult uterine cancer. METHODS: By linking statewide hospital discharge records with cancer registry data in New York, we identified 843 women with occult endometrial carcinoma and 334 women with occult uterine sarcoma who underwent a hysterectomy or myomectomy for presumed benign indications during the period October 1, 2003, through December 31, 2013. Within this cohort, we compared disease-specific and all-cause mortality of women who underwent laparoscopic supracervical hysterectomy/laparoscopic myomectomy (LSH/LM), a surrogate indicator for uncontained power morcellation, with women who underwent supracervical abdominal hysterectomy and total abdominal hysterectomy (TAH), which did not involve power morcellation. Multivariable Cox regressions and propensity score method were used to adjust for patient characteristics. RESULTS: Among women with occult uterine sarcoma, LSH/LM was associated with a higher risk for disease-specific mortality than TAH (adjusted hazard ratio [aHR], 2.66, 95% CI, 1.11 to 6.37; adjusted difference in 5-year disease-specific survival, -19.4%, 95% CI, -35.8% to -3.1%). In the subset of women with leiomyosarcoma, LSH/LM was associated with an increased risk for disease-specific mortality compared with supracervical abdominal hysterectomy (aHR, 3.64, 95% CI, 1.50 to 8.86; adjusted difference in 5-year disease-specific survival, -31.2%, 95% CI, -50.0% to -12.3%) and TAH (aHR, 4.66, 95% CI, 1.97 to 11.00; adjusted difference in 5-year disease-specific survival, -37.3%, 95% CI, -54.2% to -20.3%). Among women with occult endometrial carcinoma, there was no significant association between surgical approach and disease-specific mortality. CONCLUSION: Uncontained power morcellation was associated with higher mortality risk in women with occult uterine sarcoma, especially in those with occult leiomyosarcoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Xu X, Lin H, Wright JD, et al. Association Between Power Morcellation and Mortality in Women With Unexpected Uterine Cancer Undergoing Hysterectomy or Myomectomy. J Clin Oncol. 2019. PMID: 31518176. doi:10.1200/JCO.19.00562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。